7 results on '"Samuels Y"'
Search Results
2. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
- Author
-
Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, Scolyer RA, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N, and Samuels Y
- Subjects
- Cell Line, Tumor, HLA-A Antigens immunology, Humans, Lymphocytes, Tumor-Infiltrating immunology, Receptors, Antigen, T-Cell immunology, ras Proteins genetics, Antigens, Neoplasm immunology, Melanoma immunology, ras Proteins immunology
- Abstract
Neoantigens are now recognized drivers of the antitumor immune response. Recurrent neoantigens, shared among groups of patients, have thus become increasingly coveted therapeutic targets. Here, we report on the data-driven identification of a robustly presented, immunogenic neoantigen that is derived from the combination of HLA-A*01:01 and RAS.Q61K. Analysis of large patient cohorts indicated that this combination applies to 3% of patients with melanoma. Using HLA peptidomics, we were able to demonstrate robust endogenous presentation of the neoantigen in 10 tumor samples. We detected specific reactivity to the mutated peptide within tumor-infiltrating lymphocytes (TILs) from 2 unrelated patients, thus confirming its natural immunogenicity. We further investigated the neoantigen-specific clones and their T cell receptors (TCRs) via a combination of TCR sequencing, TCR overexpression, functional assays, and single-cell transcriptomics. Our analysis revealed a diverse repertoire of neoantigen-specific clones with both intra- and interpatient TCR similarities. Moreover, 1 dominant clone proved to cross-react with the highly prevalent RAS.Q61R variant. Transcriptome analysis revealed a high association of TCR clones with specific T cell phenotypes in response to cognate melanoma, with neoantigen-specific cells showing an activated and dysfunctional phenotype. Identification of recurrent neoantigens and their reactive TCRs can promote "off-the-shelf" precision immunotherapies, alleviating limitations of personalized treatments.
- Published
- 2021
- Full Text
- View/download PDF
3. Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.
- Author
-
Kalaora S and Samuels Y
- Subjects
- Algorithms, Antigens, Neoplasm genetics, Antigens, Neoplasm immunology, Cell Culture Techniques instrumentation, Cell Culture Techniques methods, Chromatography, High Pressure Liquid instrumentation, Chromatography, High Pressure Liquid methods, Exome genetics, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class I isolation & purification, Histocompatibility Antigens Class II genetics, Histocompatibility Antigens Class II immunology, Histocompatibility Antigens Class II isolation & purification, Humans, Hybridomas, Immunoprecipitation instrumentation, Immunoprecipitation methods, Neoplasms pathology, Proteomics instrumentation, Spectrometry, Mass, Electrospray Ionization instrumentation, Spectrometry, Mass, Electrospray Ionization methods, Tandem Mass Spectrometry instrumentation, Antigens, Neoplasm isolation & purification, Exome immunology, Neoplasms immunology, Proteomics methods, Tandem Mass Spectrometry methods
- Abstract
Neo-antigens expressed on tumors are targets for development of cancer immunotherapy strategies. Use of prediction algorithms to identify neo-antigens yields a significant number of peptides that must be validated in laborious and time-consuming methods; many prove to be false-positive identifications. The use of HLA peptidomics allows the isolation of the HLA-peptide complexes directly from cells and can be done on fresh tumor, patient-derived xerographs, or cell lines when the tissue sample is limited. This method can be used to identify both HLA class I and HLA class II or any different MHC from different species. Here we describe the steps to create the immune-affinity columns used from the process, the immunoprecipitation procedure, and also the isolation of the peptides that will be analyzed by mass spectrometry.
- Published
- 2019
- Full Text
- View/download PDF
4. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
- Author
-
Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, and Samuels Y
- Subjects
- Animals, Antigens, Neoplasm metabolism, Histocompatibility Antigens Class I metabolism, Humans, Melanoma metabolism, Melanoma pathology, Mice, Mice, Inbred NOD, Mice, SCID, T-Lymphocytes metabolism, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Antigen Presentation immunology, Antigens, Neoplasm immunology, Histocompatibility Antigens Class I immunology, Lymphocytes, Tumor-Infiltrating immunology, Melanoma immunology, T-Lymphocytes immunology
- Abstract
The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 tumors derived from seven patients with melanoma and characterize their interactions with their tumor-infiltrating lymphocytes (TIL). Our investigation of the antigenic and T-cell landscapes encompassing the TAA and neoantigen signatures, their immune reactivity, and their corresponding T-cell identities provides the first comprehensive analysis of cancer cell T-cell cosignatures, allowing us to discover remarkable antigenic and TIL similarities between metastases from the same patient. Furthermore, we reveal that two neoantigen-specific clonotypes killed 90% of autologous melanoma cells, both in vitro and in vivo , showing that a limited set of neoantigen-specific T cells may play a central role in melanoma tumor rejection. Our findings indicate that combining HLA peptidomics with neoantigen predictions allows robust identification of targetable neoantigens, which could successfully guide personalized cancer immunotherapies. Significance: As neoantigen targeting is becoming more established as a powerful therapeutic approach, investigating these molecules has taken center stage. Here, we show that a limited set of neoantigen-specific T cells mediates tumor rejection, suggesting that identifying just a few antigens and their corresponding T-cell clones could guide personalized immunotherapy. Cancer Discov; 8(11); 1366-75. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333 ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
5. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.
- Author
-
Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, and Samuels Y
- Subjects
- Humans, Antigen Presentation immunology, Antigens, Neoplasm immunology, Exome immunology, Histocompatibility Antigens Class I immunology, Peptidomimetics immunology
- Abstract
The antigenicity of cells is demarcated by the peptides bound by their Human Leucocyte Antigen (HLA) molecules. Through this antigen presentation, T cell specificity response is controlled. As a fraction of the expressed mutated peptides is presented on the HLA, these neo-epitopes could be immunogenic. Such neo-antigens have recently been identified through screening for predicted mutated peptides, using synthetic peptides or ones expressed from minigenes, combined with screening of patient tumor-infiltrating lymphocytes (TILs). Here we present a time and cost-effective method that combines whole-exome sequencing analysis with HLA peptidome mass spectrometry, to identify neo-antigens in a melanoma patient. Of the 1,019 amino acid changes identified through exome sequencing, two were confirmed by mass spectrometry to be presented by the cells. We then synthesized peptides and evaluated the two mutated neo-antigens for reactivity with autologous bulk TILs, and found that one yielded mutant-specific T-cell response. Our results demonstrate that this method can be used for immune response prediction and promise to provide an alternative approach for identifying immunogenic neo-epitopes in cancer.
- Published
- 2016
- Full Text
- View/download PDF
6. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
- Author
-
Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, and Robbins PF
- Subjects
- Alleles, Amino Acid Sequence, Animals, Antigens, Neoplasm chemistry, Autoantigens immunology, Cell Line, Disease Progression, Epitope Mapping, Epitopes, T-Lymphocyte chemistry, Epitopes, T-Lymphocyte immunology, Epitopes, T-Lymphocyte metabolism, Gene Library, Histocompatibility Antigens genetics, Histocompatibility Antigens immunology, Humans, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Neoplasms pathology, Peptides chemistry, Peptides immunology, Protein Binding immunology, Antigens, Neoplasm genetics, Antigens, Neoplasm immunology, Mutation, Neoplasms genetics, Neoplasms immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism
- Abstract
Purpose: Cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes (TIL) represents an effective treatment for patients with metastatic melanoma, with the objective regressions in up to 72% of patients in three clinical trials. However, the antigen targets recognized by these effective TILs remain largely unclear., Experimental Design: Melanoma patients 2359 and 2591 both experienced durable complete regressions of metastases ongoing beyond five years following adoptive TIL transfer. Two conventional screening approaches were carried out to identify the antigens recognized by these clinically effective TILs. In addition, a novel approach was developed in this study to identify mutated T-cell antigens by screening a tandem minigene library, which comprised nonsynonymous mutation sequences identified by whole-exome sequencing of autologous tumors., Results: Screening of an autologous melanoma cDNA library using a conventional approach led to the identification of previously undescribed nonmutated targets recognized by TIL 2359 or TIL 2591. In contrast, screening of tandem minigene libraries encoding tumor-specific mutations resulted in the identification of mutated kinesin family member 2C (KIF2C) antigen as a target of TIL 2359, and mutated DNA polymerase alpha subunit B (POLA2) antigen as a target of TIL 2591. Both KIF2C and POLA2 have been found to play important roles in cell proliferation., Conclusions: These findings suggest that the minigene screening approach can facilitate the antigen repertoire analysis of tumor reactive T cells, and lead to the development of new adoptive cell therapies with purified T cells that recognize candidate-mutated antigens derived from genes essential for the carcinogenesis., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
7. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
- Author
-
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, and Rosenberg SA
- Subjects
- Adult, Antigens, Neoplasm immunology, Epitopes, T-Lymphocyte, Female, HLA-A Antigens metabolism, Humans, Male, Melanoma immunology, Middle Aged, Adoptive Transfer, Antigens, Neoplasm genetics, Exome, Lymphocytes, Tumor-Infiltrating immunology, Melanoma therapy, Mutation
- Abstract
Substantial regressions of metastatic lesions have been observed in up to 70% of patients with melanoma who received adoptively transferred autologous tumor-infiltrating lymphocytes (TILs) in phase 2 clinical trials. In addition, 40% of patients treated in a recent trial experienced complete regressions of all measurable lesions for at least 5 years following TIL treatment. To evaluate the potential association between the ability of TILs to mediate durable regressions and their ability to recognize potent antigens that presumably include mutated gene products, we developed a new screening approach involving mining whole-exome sequence data to identify mutated proteins expressed in patient tumors. We then synthesized and evaluated candidate mutated T cell epitopes that were identified using a major histocompatibility complex-binding algorithm for recognition by TILs. Using this approach, we identified mutated antigens expressed on autologous tumor cells that were recognized by three bulk TIL lines from three individuals with melanoma that were associated with objective tumor regressions following adoptive transfer. This simplified approach for identifying mutated antigens recognized by T cells avoids the need to generate and laboriously screen cDNA libraries from tumors and may represent a generally applicable method for identifying mutated antigens expressed in a variety of tumor types.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.